For example, in a glioblastoma model, bispecific CAR T-cells targeting both interleukin-13 receptor subunit alpha-2 (IL-13Rα2) and ephrin type-A receptor 2 (EphA2) demonstrated enhanced efficacy and reduced antigen escape compared to single CAR bearing T-cells [94]. This evidence concerns the gene EPHA2 and glioblastoma.